Browse by category

The preliminary findings from a multi-centre study assessing magnetic gastroileostomy bipartition (MagGI procedure) as a revisional option for suboptimal sleeve gastrectomy (SG), suggest that SG-revisional MagGI was technically feasible and achieved promising excess weight loss of 66.0%. Self-aligning GT Metabolic MagDI System magnets fused together The study was conducted in adults (body mass index [BMI, kg/m2] ≥30.0–≤50.0). The 90-day primary feasibility endpoint was magnet

For patients undergoing body contouring surgery to remove excess abdominal skin after significant weight loss, use of GLP-1 weight-loss medications may have mixed effects on complication risks, according to a study by researchers from West Virginia University School of Medicine, Morgantown, WV. Share of all patients who take a GLP-1 RA by state. Credit: Plastic & Reconstructive Surgery (2025). DOI: 10.1097/prs.0000000000012405 "As GLP-1 receptor agonist (GLP1ra) medications b

Dr Alexander Parr, a board-certified general and bariatric surgeon with the Broward Health Physician Group, has reached a milestone achievement, performing his 2,555th robotic-assisted procedure using the Da Vinci Surgical System at Broward Health Imperial Point, marking a significant landmark in his career and underscoring Broward Health’s commitment to advanced surgical technology. Alexander Parr “Reaching 2,555 robotic-assisted procedures is an exciting milestone, but more

The last participant has been randomised and dosed in Amylyx Pharmaceuticals’ pivotal Phase 3 LUCIDITY clinical trial of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist with an FDA Breakthrough Therapy Designation in post-bariatric hypoglycemia (PBH). LUCIDITY is a 16-week, multicentre, randomised, double-blind, placebo-controlled trial evaluating the efficacy and safety of avexitide in adults with PBH following Roux-en-Y gast

Both Roux-en-Y gastric bypass (RYGB) and single-anastomosis duodeno-ileal bypass (SADI-S) are effective and safe revisional options after sleeve gastrectomy (SG), according to researchers from Hamad Medical Corporation, Doha, Qatar. They noted that SADI-S offers superior long-term weight-loss and metabolic outcomes, whereas RYGB remains preferable for patients with significant or persistent GERD. “Tailoring revisional procedure selection to patient characteristics and ensurin

Researchers from Saudi Arabia have reported that although general awareness of obesity’s metabolic impact is high, understanding of the therapeutic role of metabolic bariatric surgery for T2DM remained limited. Despite that fact that injectable therapies were more frequently preferred than surgical options, their study did not find definitive conclusions regarding the underlying drivers of these preferences. “These findings highlight the need for structured public education i